medline.ch Gastroenterologie Leber Neoplasie

	Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration. Front Immunol Ying H, Pan Y, Zhu X, Xuan Q. PMID: 42099608 [PubMed - indexed for MEDLINE]
	Inflammation in hepatocellular carcinoma progression: a "Single Wick, dual interwoven strands" regulatory framework. Front Immunol Wu C, Dong J, Sui S, Tan X, Zhu N. PMID: 42099598 [PubMed - indexed for MEDLINE]
	Analysis of colorectal liver metastases in photon-counting detector CT - optimizing imaging through spectral reconstruction. Cancer Imaging Moos M, Emrich T, Nguyen M, Steinmetz S, Kloeckner R, Hahn F, Steiner P, Scholz C, Moehler M, Lang H, Bäuerle T, Jorg T, Müller L. PMID: 42098885 [PubMed - indexed for MEDLINE]
	Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. PLoS One Nishioka C, Tahata Y, Maesaka K, Kai M, Shirai K, Murai K, Makino Y, Saito Y, Nozaki Y, Nakabori T, Ishida H, Yakushijin T, Iio S, Tatsumi N, Imanaka K, Kakita N, Sakamori R, Hosui A, Miyazaki M, Matsumoto K, Nakahara M, Doi Y, Sakakibara M, Hikita H, Kodama T, Takehara T. PMID: 42096473 [PubMed - indexed for MEDLINE]
	Local and systemic cytokine signatures for outcome prediction after transarterial chemoembolization in hepatocellular carcinoma. Theranostics Yilmaz EY, Schmidt R, Heidemann L, He Y, Liu Y, Sulejmani O, Müller DN, Wilhelm A, Auer TA, Hamm CA, Abosabie SAS, Abosabie SA, Gebauer B, Savic LJ. PMID: 42094598 [PubMed - indexed for MEDLINE]
	Fenugreek seed extract-doxorubicin synergy against hepatocellular carcinoma in HepG2 cells: in vitro and in silico mechanistic studies. BMC Complement Med Ther Ragab W, Mahmoud K, Allam RM, Qayed WS, Gomaa OM, El-Hawary SS, Moawad AS, Mohammed R. PMID: 42092913 [PubMed - indexed for MEDLINE]
	Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial. Signal Transduct Target Ther Lu S, Zhang W, Li J, Zhang Z, Hu B, Li X, Cao Y, Wang Z, Wang Z, Ye H, Qu B, Li Y, Ma G, Wan T, Liu Z, Liu B, Xu Y, Tang H, Zhao X, Pan L, Yang L, Yuan J, Chen R, Bian X. PMID: 42091859 [PubMed - indexed for MEDLINE]
	Nutritional Risk Assessed by Royal Free Hospital-Nutritional Prioritizing Tool Predicts Survival in Cirrhosis With or Without Hepatocellular Carcinoma. J Korean Med Sci Park HJ, Jung JK, Noh J, Kim Y, Lee SU, Yun BC, Lee JW, Kim HJ, Seo KI. PMID: 42089136 [PubMed - indexed for MEDLINE]
	Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era. BMJ Open Gastroenterol Chen S, Shen L, Qi H, Hu P, Cao F, Xie L, Wang Y, Fan W. PMID: 42086291 [PubMed - indexed for MEDLINE]
	Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma. Radiology Berman ZT, De la Garza-Ramos C, Montazeri SA, Malone CD, Sandow T, Gimenez J, Young S, Fidelman N, Pianka KT, Sher A, Alamuri T, Chan SM, Vakil P, Wang M, Abounorinejad F, Som A, Johnson GE, Padia SA, Kim E, Toskich BB. PMID: 42084516 [PubMed - indexed for MEDLINE]
	Diffusion-weighted Imaging of the Liver: Primed for New Business. Radiology Brunsing RL, Syed AB, Hargreaves BA, Ennis DB. PMID: 42084512 [PubMed - indexed for MEDLINE]
	Risk of Intrahepatic and Extrahepatic Cancers in HepatitisÂ C Virus Infection: A Nationwide Cohort Study in Korea, 2005-2023. Liver Int Park Y, Kim BW, Oh JK, Kim BH, Park SJ, Kim KA, Ki M. PMID: 42084000 [PubMed - indexed for MEDLINE]
	Identification of CD4+ T Cell-Related Biomarkers and Mechanisms for Hepatoma. Comb Chem High Throughput Screen Zhang Z, Guo L, Luo J, Zheng J, Zeng H. PMID: 42083412 [PubMed - as supplied by publisher]
	Tri-Scenario-Based MAICOHAN Strategy for Minimally Invasive Extended Left Hepatectomy. Asian J Endosc Surg Yamamoto Y, Morimura R, Imamura T, Kubo H, Shibata R, Inoue H, Kurashima K, Nishibeppu K, Nanishi K, Kiuchi J, Shimizu H, Arita T, Kosuga T, Konishi H, Fujiwara H, Shiozaki A. PMID: 42082340 [PubMed - indexed for MEDLINE]
	Blood protein biomarkers in hepatocellular carcinoma: progress and challenges. PeerJ Zhang L, Zhang M, Bao Y, Yang J, Luo T, Zhang Y, Wang Y, Liu P, Guo X. PMID: 42079726 [PubMed - indexed for MEDLINE]
	Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis. Front Immunol Zhang Q, Lei Z, Qing H, Xie X. PMID: 42079632 [PubMed - indexed for MEDLINE]
	RFXANK: A Novel Immune-Related Biomarker for Hepatocellular Carcinoma. Genes (Basel) Qu T, Tian L. PMID: 42074524 [PubMed - indexed for MEDLINE]
	Graphene Oxide-Antisense miR-21 Nanosystem Modulates Gene Expression and Suppresses Tumorigenesis in HepG2-Derived CAM Xenografts. Biomolecules Trischitta P, Nasi, Pennisi R, Costa M, Sciortino MT, Kutwin M. PMID: 42072644 [PubMed - indexed for MEDLINE]
	Prognostic and clinicopathological significance of CD133 in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) Kang B, Liang D, Liu D. PMID: 42071890 [PubMed - indexed for MEDLINE]
	Repositioned donafenib versus standard regorafenib for second-line HCC treatment: A matched cohort study. Medicine (Baltimore) Chen X, Li X, Li X, Jiang Y, Xie Q, Xie P, Cao L. PMID: 42071878 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 76035

Seite 1 von 3802

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung